Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

To be considered for this study, you must be at least 18 years old and have advanced melanoma that has spread or cannot be removed by surgery. Your doctors must also agree that you are suitable for standard treatment with Pembrolizumab. Importantly, your overall health should be reasonably good, meaning you can look after yourself for most daily activities, and your organs like your heart, liver, and kidneys are working well.

There are also some specific medical requirements, such as having certain types of cancer measurable by scans, having had any previous radiotherapy at least two weeks before starting the study, and having a confirmed status of a specific gene change (BRAF V600 mutation) in your melanoma cells. You would also need to have a life expectancy of at least three months.

However, you couldn't join if your melanoma started in your eye. There are also specific rules around pregnancy testing and contraception for both men and women who could potentially become pregnant or cause a pregnancy, to ensure safety throughout the study.

If you decide to take part, you would be randomly assigned to one of two groups: either you'd receive the new treatment (EIK1001) plus Pembrolizumab, or you'd receive a placebo (dummy treatment) plus Pembrolizumab. Neither you nor your doctor would know which group you are in.

The study involves regular visits to the clinic for medical check-ups, blood tests, and scans (like CT or MRI). These are to monitor your health, how the treatment is working, and to check for any side effects. You'll receive the study medications through an infusion (into a vein) on a set schedule. The total duration of your participation, including follow-up appointments after your last dose, will be explained in detail by the study team.